Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof

A technology for neural precursor cells and ischemic diseases, which can be used in medical preparations containing active ingredients, nervous system cells, cardiovascular system diseases, etc. Effects on number and microvascular concentration

Pending Publication Date: 2017-05-24
S-BIOMEDICS CO LTD
View PDF10 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still no mention of how the neural precursor cells differentiated from embryonic stem cells or the culture medium of neural precursor cells can improve the function of transplanted disease models

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof
  • Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof
  • Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1. The therapeutic effect of polysialic acid neural cell adhesion molecule-positive neural precursor cells on ischemic diseases and neuroinflammatory diseases

[0079] experimental method

[0080] NPC derived from human mesenchymal stem cells and human embryonic stem cells PSA-NCAM+ Cell Culture and Differentiation

[0081] The use of human cells was approved by the Institutional Review Board (IRB No. 4-2008-0643). Human bone marrow was harvested from the posterior iliac crest of healthy adult volunteers who gave informed consent. The acquisition method is briefly explained as follows, that is, bone marrow mononuclear cells are separated by density gradient centrifugation (GE Healthcare, Uppsala, Sweden), and the bone marrow is placed in DMEM fed with 10% fasting blood sugar (FBS) (Gibco, Grand Island, NY). After monocytes are incubated at a temperature of 37 °C in an atmosphere containing 5% CO 2 cultured in humidified air. After 24 hours, wash and remove ...

Embodiment 2

[0122] Example 2. The therapeutic effect of ischemic diseases and neuroinflammatory diseases targeting the secretome of neural precursor cells

[0123] Experimental materials and experimental methods

[0124] NPCs derived from human embryonic stem cells PSA-NCAM+ Acquisition of cells

[0125] The use of human cells was approved by the Institutional Review Board (IRB No. 4-2008-0643). For neural induction, on human embryonic stem cell medium (Invitrogen) without basic fibroblast growth factor, in the presence of 5 μM free base (Sigma, St. Louis, MO) and 5-10 μM SB431542 (Calbiochem, SanDiego, CA) suspension cultured various embryoid bodies (embryoid bodies, EBs) derived from human embryonic stem cells and iPSCs for 4 days, after inputting The 1XN2 (Invitrogen) medium of basic fibroblast growth factor was adsorbed on matrigel-coated culture dishes (BD Biosciences, Bedford, MA) for about 5 days (Kim, D.S., Lee, D.R., Kim, H.S., et al. al. (2012). Highly pure and expandable PS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention provides a composition for treating ischemic diseases or neurogenic inflammation. PSA-NCAM-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The PSA-NCAM-positive neural progenitor cells can be simply isolated by using an anti-PSA-NCAM-antibody, and exhibit excellent angiogenic and anti-inflammatory activities compared with mesenchymal stem cells, and thus can be useful as a composition for effectively treating ischemic diseases caused by a vascular injury and nerve damage diseases caused by inflammation. In addition, a secretome of the neural progenitor cells of the present invention reduces the ischemic injury site and allows a neurological function to recover, and thus can be used as an agent for treating ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation.

Description

technical field [0001] The present invention relates to a composition for treating ischemic diseases or neuroinflammatory diseases containing neural precursor cells or their secretome (Secretome) as an active ingredient. Background technique [0002] Stem cells are considered as promising therapeutic candidates for various diseases due to their multi-differentiation potential. For example, mesenchymal stem cells (mesenchymal stem cells, MSCs) have the characteristics of many nutritional factors that can be easily obtained and isolated, promote angiogenesis, and inhibit inflammation (Caplan, A.I., & Dennis, J.E. (2006). Journal of Cellular Biochemistry, 98 , 1076-1084). These properties of mesenchymal stem cells are applied to the research of treating human diseases. According to recent studies, mesenchymal stem cells have been used in many animal models and human clinical treatment (Chen, J., Li, Y., Katakowski, M., et al. (2003). Journal of Neuroscience Research, 73, 778-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/30A61K39/395A61P9/10A61P9/00
CPCA61K2039/515C12N5/0623C12N2500/25C12N2500/90C12N2501/115C12N2506/02C12N2506/45C12N2502/02C12N2502/1358C12N2533/90C12N2501/15C12N2501/727A61K35/30A61K9/0019A61K35/12A61K39/395
Inventor 金东旭金汉洙
Owner S-BIOMEDICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com